1132832-76-8 Usage
General Description
The chemical "2-{3-[5-(4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-3,4,5-tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-ol" is a complex compound with a tetrahydro-pyran-2-ol core structure. It contains a mixture of trimethylsilanyloxy and trimethylsilanyloxymethyl groups, as well as a fluoro-phenyl and thiophen-2-ylmethyl substituents. 2-{3-[5-(4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-3,4,5-tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-ol is likely to have various chemical properties and potential applications, given its unique structure and combination of functional groups.
Check Digit Verification of cas no
The CAS Registry Mumber 1132832-76-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,3,2,8,3 and 2 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1132832-76:
(9*1)+(8*1)+(7*3)+(6*2)+(5*8)+(4*3)+(3*2)+(2*7)+(1*6)=128
128 % 10 = 8
So 1132832-76-8 is a valid CAS Registry Number.
1132832-76-8Relevant articles and documents
Preparation method of Canagliflozin intermediate
-
Paragraph 0115-0122; 0143-0144, (2019/11/13)
The invention provides a preparation method of a Canagliflozin intermediate. According to the method, a stable reagent is added to an organic solvent mixing system containing 2-(5-BroMo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene(compound III) and n-Butyllithium, so that the phenomenon that when the n-Butyllithium is used, reaction products are complex, and more by-products exist, can be improved.The method is stable and high in repetition rate, the purity of the obtained intermediate is as high as 94.7%, the continuous reaction yield can achieve 93.8%, and the preparation method has industrial application prospects.
PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT
-
Page/Page column 78-79, (2009/04/25)
The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.